Skip to content

Study for Checking the REal-world Echocardiography to indeNtify hidden Hypertrophic CardioMyopathy

Study for Checking the REal-world Echocardiography to indeNtify hidden Hypertrophic CardioMyopathy - SCREEN-HCM

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000057757
Enrollment
9000
Registered
2025-05-10
Start date
2025-05-10
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients who undergo echocardiography

Interventions

None listed

Sponsors

Juntendo University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Adults aged 20 years or older who underwent transthoracic echocardiography in the physiological examination department of our hospital between April 1, 2023, and September 30, 2023, and who did not meet any of the exclusion criteria.

Exclusion criteria

Exclusion criteria: Patients whose echocardiographic data are unavailable or inadequate for analysis.

Design outcomes

Primary

MeasureTime frame
The number and prevalence of patients who were screened as having HCM by AI-based echocardiographic analysis software (US2.ai) but were not clinically identified as HCM based on manual echocardiographic measurements and past medical records.

Secondary

MeasureTime frame
Secondary outcome 1: The number of patients clinically identified as having HCM and those not identified, based on manual echocardiographic measurements and past medical records. Secondary outcome 2: The number of patients identified as HCM by AI-based echocardiographic analysis and their clinical characteristics. Secondary outcome 3: The number of patients clinically identified as having HCM based on manual echocardiographic measurements and past medical records, along with their clinical characteristics. Secondary outcome 4: The clinical characteristics of patients identified as HCM by AI-based analysis but not by manual echocardiographic measurements. Secondary outcome 5: Clinical performance of the AI-based analysis in diagnosing HCM, including positive predictive value, sensitivity, and specificity. Secondary outcome 6: Accuracy of AI-based analysis in measuring echocardiographic parameters related to cardiac hypertrophy.

Countries

Japan

Contacts

Public ContactNobuyuki Kagiyama

Juntendo University Hospital Department of Cardiovascular Biology and Medicine

kgnb_27_hot@yahoo.co.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026